研究单位：[1]Sumitomo Pharma (Suzhou) Co.,Ltd.[2]Beijing Huilongguan Hospital Beijing,Beijing,China,100096[3]Peking University Sixth Hospital Beijing,Beijing,China,100191[4]First Affiliated Hospital of Kunming Medical University Kunming,Yunnan,China,650032[5]Tianjin Anding Hospital Tianjin,Tianjin,China,300222[6]West China Hospital,Sichuan University Chengdu,Sichuan,China,610041[7]Xi'an Mental Health Center Xi'an,Shanxi,China,710061[8]Shanghai Mental Health Center Shanghai,Shanghai,China,200030[9]Nanjing Brain Hospital Nanjing,Jiangsu,China,210029[10]Wuxi Mental Health Center Wuxi,Jiangsu,China,214000
研究目的：
This is a randomized, double-blind, double-dummy, parallel- controlled, adjustable dose, non-inferiority and multicentre study designed to evaluate the efficacy and safety of lurasidone on schizophrenia for 6 weeks treatment, and to compare with risperidone.
